Detection of c-Ki-ras mutations in bile samples from patients with pancreatic and biliary cancers

S O’Mahony, M Longfellow, M J McMahon, A T R Axon, P Quirke

Abstract

Aim—To determine whether c-Ki-ras mutations can be detected in bile from patients with biliary strictures caused by pancreatic cancer and other biliary tumours, with a view to developing bile c-Ki-ras mutations as a non-invasive diagnostic marker of pancreatic cancer.

Methods—Bile was collected from 89 subjects (47 controls (including patients with bile duct stones or benign stricture), 20 patients with pancreatic cancer, 11 with cholangiocarcinoma, five with ampullary cancer, and six with metastatic biliary obstruction) referred for endoscopic retrograde cholangiopancreatography. DNA was extracted from bile and c-Ki-ras codon 12 mutations were detected using PCR and a restriction enzyme digestion method.

Results—c-Ki-ras mutations were detected in 10 (50%) of 20 patients with pancreatic cancer, in one (9%) of 11 with cholangiocarcinoma, and in two (33%) of six patients with metastatic biliary obstruction (primary tumours: colon and prostate). C-Ki-ras mutations were not detected in the controls and patients with ampullary cancer.

Conclusions—The sensitivity of this test is too low at 50% to recommend its use clinically, but with refinement it has potential as a diagnostic marker for pancreatic cancer.


Keywords: Bile, c-Ki-ras, pancreatic cancer, biliary cancer.

Most (over 90%) of pancreatic adenocarcinomas harbour mutations in codon 12 of the c-Ki-ras gene. Recent studies have reported the presence of the oncogene in pancreatic juice and pancreatic duct brushings in over 90% of patients with pancreatic cancer, suggesting that the oncogene might be useful as a diagnostic marker of pancreatic cancer. Pancreatic juice is, however, relatively difficult to obtain endoscopically, and performing brushings of the pancreatic duct adds significantly to procedure time of endoscopic retrograde cholangiopancreatography (ERCP). Bile is easy to collect endoscopically, particularly when a stent is inserted. Obstructive jaundice is a frequent presentation of pancreatic cancer, and these patients are generally managed by ERCP, which has the advantage of being a combined diagnostic and therapeutic modality. The aim of our study was to determine whether c-Ki-ras mutations can be detected in bile from patients with biliary strictures caused by pancreatic cancer and other biliary tumours, with a view to developing bile c-Ki-ras mutations as a non-invasive diagnostic marker of pancreatic cancer.

Methods

Bile was collected from a total of 89 subjects referred for ERCP. Demographic details are shown in the table. These 89 subjects included 47 controls (20 patients with pancreatic cancer, 11 with cholangiocarcinoma, five with ampullary cancer, and six with biliary obstruction caused by metastases). The control group consisted of 30 patients with bile duct calculi (11 patients with a normal biliary tree, one patient with a postoperative biliary leak, and three with benign biliary strictures caused by chronic pancreatitis, Mirizzi syndrome, and iatrogenic post-cholecystectomy bile duct injury). The patient with chronic pancreatitis had previously undergone a cystejejunostomy for pseudocyst following alcoholic pancreatitis. In the 20 patients with pancreatic cancer, a tissue diagnosis was achieved in four only: three by laparotomy and the other by ascitic fluid cytology. Percutaneous fine-needle aspiration biopsy was unsuccessful in four cases, the material obtained being insufficient for diagnosis, consisting of necrotic tissue and red blood cells. The diagnosis of pancreatic cancer in the remaining 16 was based on radiological (computed tomography/ERCP) appearances, and clinical follow up: all 20 patients have died, with a median survival of six months (range one to 16 months). Four patients underwent surgery: one had a Whipple’s procedure, two had palliative biliary by-pass procedures, and the other a gastrojejunostomy. Of the 11 patients with cholangiocarcinoma, tissue diagnosis was achieved in one only, by laparoscopic biopsy of omental deposits. In the remaining 10 patients, diagnosis was based on typical radiological appearances (all had hilar strictures) and clinical follow up: nine of these 10 patients have died, with a median survival of five months (range one to 18 months). One patient is alive at 19 months following stenting, and none underwent surgery. In the five patients with ampullary cancer, tissue diagnosis was achieved in all by endoscopic biopsy. In the six patients with metastatic biliary obstruction,
Detection of c-Ki-ras mutations in bile

BstN1 digest: the samples are run in pairs of digested and undigested products (even-numbered lanes contain digested products). Lanes 2, 6 and 10 contain samples with c-Ki-ras codon 12 mutations. Lanes 1 and 12, 100 base pair marker.

Results

The primary tumours were colon (n = 3), oesophagus (n = 1), stomach (n = 1), and prostate (n = 1).

### RAS MUTATION ANALYSIS

**DNA extraction**

Bile was collected endoscopically at ERCP. In those cases where a biliary stent was inserted, bile was aspirated via the stent "pusher" tube. Otherwise, bile was collected via a standard cannula. The bile was centrifuged, and the supernatant discarded. The sediment was collected in an Eppendorf tube and incubated with 2 mg/ml protease K (Sigma, Poole, Dorset, UK) and 1% sodium dodecyl sulphate for 24 hours at 37°C. The DNA was extracted using phenol chloroform extraction and ethanol precipitation. The DNA pellet was dissolved in 25 μl water and amplified by PCR.

**Polymerase chain reaction**

Primer sequences described by Jiang et al contained altered base pairs which create restriction enzyme digestion sites that permit the detection of mutations in the first two bases of c-Ki-ras codon 12. The primers were synthesised on an Applied Biosystems DNA synthesiser. The DNA was amplified using PCR to produce a 157 base pair fragment containing c-Ki-ras codon 12. The PCR conditions have been described previously. In each PCR a negative control was included in which the DNA was omitted. A volume of 12 μl of the PCR product was then visualised on a 2% GTG agarose gel stained with ethidium bromide.

**BstN1 restriction enzyme digestion**

In a total volume of 25 μl, 16 μl of the PCR product was digested with BstN1 at 60°C overnight under the conditions recommended by the enzyme suppliers (Boehringer Mannheim, UK). The digestion products were analysed on a 3% Nu Sieve agarose gel (FMC Bioproducts) stained with ethidium bromide. Sample analysis on agarose gel is shown in the figure.

### Discussion

c-Ki-ras mutations were detected in patients with malignant disease (or presumed malignant disease) only. In relation to pancreatic cancer the sensitivity (50%) was disappointing, given the high prevalence (>90%) of c-Ki-ras mutations in pancreatic cancer. There are two possible explanations for the low sensitivity: (1) low cellularity in some bile samples, and (2) relative insensitivity of the PCR technique. It is likely that brushings of biliary strictures would be more likely to contain tumour cells than bile—biliary brush cytology has a much higher sensitivity compared with bile exfoliative cytology in the diagnosis of malignant bile duct strictures. The PCR technique we have used detects mutations at codon 12 only. It is likely that more sophisticated molecular techniques (for example, amplification refractory mutation system, single strand conformation polymorphism, DNA ligase PCR) or more sensitive detection methods (for example, gene scanning on a DNA sequencer) might increase the mutation positivity rate, and thus the value of the test.

### RAS mutations were detected in patients with metastatic biliary obstruction, and in one patient with cholangiocarcinoma. The presence of the oncogene therefore does not establish a definitive diagnosis, but in the appropriate clinical setting is strong evidence of pancreatic cancer. There was, however, a small number (three) of patients with benign biliary strictures.

The tissue diagnosis rate in our patients with pancreatic cancer was low at 20%, but a positive tissue diagnosis is achieved in only a minority of patients with pancreatic cancer in this country—for example, in the Yorkshire region, of patients registered with the Regional Cancer Registry in 1993 and 1994, a positive tissue diagnosis was achieved in only 35-6% and 36-4%, respectively (Yorkshire Regional Cancer Registry: personal communication). In summary, we have detected bile c-Ki-ras mutations in 10 of 20 patients with pancreatic cancer. The sensitivity (50%) is therefore too low to recommend the clinical application of this test, but this approach has potential as a means of establishing a diagnosis at the molecular level in patients with pancreatic cancer.

<table>
<thead>
<tr>
<th>Demographic details of patients and c-Ki-ras mutation positivity rates</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subject group</strong></td>
</tr>
<tr>
<td>Controls (n = 47)</td>
</tr>
<tr>
<td>Pancreatic carcinoma (n = 20)</td>
</tr>
<tr>
<td>Cholangiocarcinoma (n = 11)</td>
</tr>
<tr>
<td>Ampullary carcinoma (n = 5)</td>
</tr>
<tr>
<td>Metastases (n = 6)</td>
</tr>
</tbody>
</table>
This work was supported by the Ivy Hobson Bequest from the Special Trustees of the United Leeds Teaching Hospitals NHS Trust. We are grateful to the referring physicians and surgeons for allowing us to study patients under their care. We thank the Endoscopy Nurses of the Leeds General Infirmary for their assistance in specimen collection.


